Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14169314 | 0.90 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL352 | 0.88 | AGTR1 (0.64) | AGTR1AGTR2 | |
| SCHEMBL201 | 0.87 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL11100306 | 0.87 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL3874586 | 0.85 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL16456600 | 0.84 | AGTR1 (0.63) | AGTR1AGTR2 | |
| SCHEMBL653 | 0.84 | AGTR1 (0.62) | AGTR1AGTR2 | |
| SCHEMBL159 | 0.84 | AGTR1 (0.81) | AGTR1AGTR2 | |
| SCHEMBL276 | 0.84 | AGTR1 (0.60) | AGTR1AGTR2 | |
| SCHEMBL156 | 0.82 | AGTR1 (0.58) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041832-B2 | Processes for preparing losartan and losartan potassium | TAVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-09 | — | — | US | claimed |
| EP-1474417-B1 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMA (IL) | 2006-03-22 | — | — | EP | claimed |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-02-19 | — | — | US | claimed |
| EP-0643704-B1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | DU PONT (US) | 2003-09-17 | — | — | EP | claimed |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | SALTIGO GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | SALTIGO GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-8030520-B2 | Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide | SALTIGO GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8030520-B2 | Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide | SALTIGO GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-7915425-B2 | Process for the preparation of losartan | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-03-29 | — | — | US | disclosed |
| US-7868180-B2 | Process for the preparation of sartan derivatives and intermediates useful in such process | KRKA, D.D. NOVO MESTO (SI) | 2011-01-11 | — | — | US | disclosed |
| US-20100222597-A1 | Process for the preparation of losartan | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20090247764-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | SALTIGO GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| WO-1995026724-A1 | IMPROVEMENT OF INSULIN SENSITIVITY WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | EIDE IVAR KONRAD (NO) | 1995-10-12 | — | — | WO | disclosed |
| WO-1995026188-A1 | TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | MERCK & CO., INC. (US) | 1995-10-05 | — | — | WO | disclosed |
| WO-1995017396-A1 | POLYMORPHS OF LOSARTAN AND THE PROCESS FOR THE PREPARATION OF FORM II OF LOSARTAN | MERCK & CO., INC. (US) | 1995-06-29 | — | — | WO | disclosed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | disclosed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
| US-5206374-A | Process for preparing tetrazolylphenylboronic acid intermediates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247764-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | MLX, PYM1, CBR3 | AGTR1 930/4885AGTR2 1258/4885 |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | REN, ACE, AGT | AGTR1 4/4885AGTR2 6/4885 |
| US-20120046471-A1 | PROCESS FOR PREPARING ORGANIC COMPOUNDS BY A TRANSITION METAL-CATALYSED CROSS-COUPLING REACTION OF AN ARYL-X, HETEROARYL-X, CYCLOALKENYL-X OR ALKENYL-X COMPOUND WITH AN ALKYL, ALKENYL, CYCLOALKYL OR CYCLOALKENYL HALIDE | TIMCC, ZFX, TSNAX | AGTR1 1347/4885AGTR2 1800/4885 |
| US-20100222597-A1 | Process for the preparation of losartan | AGT, ACE, AGTR1 | AGTR1 3/4885AGTR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.